Skip to main content

IMI impact on Ebola

This online event focused on how Innovative Medicines Initiative (IMI) projects are delivering results to advance the development and uptake of Ebola vaccines.

Vial containing first dose of prime vaccine, credit Alexandra Donaldson, LSHTM
Vial containing first dose of prime vaccine, credit Alexandra Donaldson, LSHTM



About Ebola research in IMI projects

Ebola virus disease is a rare and deadly disease caused by infection with one of the Ebola virus strains. The virus spreads in the human population through direct human-to-human contact with the bodily fluids of infected patients who are showing symptoms.

The Ebola epidemic of 2014-2015 was unprecedented in its scale and geographical distribution.  The epidemic highlighted the need for research into better vaccines, diagnostics and treatments to stop future epidemics in their tracks.

Since then, IMI projects have been involved in testing the safety, immunogenicity and durability of vaccines.  Other projects focused on reducing the onerous conditions for vaccine storage and transport, preparing for large-scale manufacture of vaccines and even running community engagement campaigns for the success of clinical trials. IMI also launched projects focused on developing new diagnostic tests for Ebola.

This event features IMI project results that contributed to the successful development of Ebola vaccines, and the creation of a communication strategy and tools to promote the acceptance and uptake of new Ebola vaccines.

The event is part of a series of live sessions that IHI is organising on the impacts of IMI in different fields. 

The session focused on projects supported by the Innovative Medicines Initiative, a partnership between the European Union and the European pharmaceutical industry.





15:00-15:10 Introduction and welcome

How IMI EBOVAC projects have impacted Ebola research


Questions and answers

16:25-16:30 Closing remarks





Session recording and presentation





Meet the speakers
blank speaker
Cynthia Robinson

Senior Medical Director

Janssen Vaccines & Prevention

blank speaker
Deborah Watson-Jones

Professor of Clinical Epidemiology & International Health

London School of Hygiene & Tropical Medicine, UK

Rodolphe Thiébaut

Professor of Public Health and Biostatistics

Université de Bordeaux

Annik Willems

Programme Leader


Bailah Leight

Head of the Community Health Department

College of Medicine and Allied Health Sciences (COMAHS)

Oussama Karroum

Scientific Project Officer, IHI JU

Event moderator